Pneumovax 23

Pneumovax 23

vaccine, pneumococcal


Merck Sharp & Dohme


Zuellig Pharma
Concise Prescribing Info
Purified capsular polysaccharides from the 23 most prevalent invasive pneumococcal types
Immunisation against pneumococcal disease caused by those pneumococcal types included in the vaccine. Immunocompetent individuals ≥2 yr: Person w/ chronic CV disease, chronic pulmonary disease or DM, alcoholism, chronic liver disease or CSF leaks, functional or anatomical asplenia; person living in special environments or social settings; routine vaccination for person ≥50 yr. Immunocompromised individuals ≥2 yr including those w/ HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure or nephrotic syndrome; those receiving immunosuppressive chemotherapy & have received an organ or bone marrow transplant. Revaccination in person ≥2 yr at high risk of serious pneumococcal infection & those likely to have a rapid decline in pneumococcal antibody levels after at least 5 yr of 1st dose of pneumococcal vaccine.
Dosage/Direction for Use
Single 0.5 mL dose SC or IM (preferably in the deltoid muscle or lateral mid-thigh). Not to be inj IV.
Hypersensitivity. Epinephrine inj (1:1000) must be immediately available should an acute anaphylactoid reaction occur.
Special Precautions
Not to be inj IV or intradermally. Avoid intravascular administration. Expected serum antibody response may not be obtained in person receiving immunosuppressive therapy. Severely compromised cardiac &/or pulmonary function. Delay usage in febrile resp illness or other active infection. Antibiotic prophylaxis against pneumococcal infection should not be discontinued after vaccination w/ Pneumovax 23 when required. Severe renal & hepatic impairment. Pregnancy & lactation. Not recommended in childn <2 yr. Frail elderly individuals w/ multiple co-morbid conditions.
Adverse Reactions
Inj site reactions eg, soreness, erythema, warmth, swelling & local induration; decreased limb mobility; peripheral edema. Fever; asthenia/fatigue; myalgia; headache.
ATC Classification
J07AL01 - pneumococcus, purified polysaccharides antigen ; Belongs to the class of pneumococcal bacterial vaccines.
Pneumovax 23 vaccine (inj) (vial) 0.5 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in